How to Manage Low Estriol Levels in Pregnancies, One Center Experience

dc.authoridYilmaz Gulec, Elif/0000-0003-0872-3898
dc.authoridOZTURK, Fatma Nihal/0000-0002-9691-5736
dc.contributor.authorGulec, Elif Yilmaz
dc.contributor.authorGezdirici, Alper
dc.contributor.authorAyaz, Akif
dc.contributor.authorOzturk, Fatma Nihal
dc.contributor.authorPolat, Ibrahim
dc.date.accessioned2025-05-10T19:53:23Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjective: Low estriol (uE3) levels in the second-trimester screening for Down syndrome may be the result of fetal demise, congenital abnormalities, or some genetic hormonal disorders of the fetus. Although X-linked ichthyosis, a microdeletion syndrome with mild ichthyosis, which causes steroid sulfatase (STS) deficiency, is the most common genetic cause, second-trimester screening tests calculate the risk for a less common and severe disorder known as the Smith Lemli Opitz syndrome (SLOS). We aimed to investigate the outcomes of pregnancies with low uE3 levels in Down syndrome screening and emphasize the high prevalence of STS deficiency instead of SLOS in such cases.Methods: Fifteen pregnancies with very low uE3 levels and high risk for trisomy and/or SLOS in screening tests were evaluated and tested for STS deficiency and SLOS.Results: Seven of the pregnancies had STS microdeletion syndrome, while additional two cases were supposed to have STS gene mutation according to family and/or postnatal history. Although one fetal death was recorded, no chromosomal abnormality, SLOS, or congenital malformation was recorded in our series.Conclusions: SLOS is a very severe and rare syndrome. The risk estimation for SLOS in screening tests causes stress for pregnant women and healthcare givers. We recommend the addition of risk estimation for STS deficiency when a low uE3 level is detected in the screening test.
dc.identifier.doi10.4274/MMJ.galenos.2022.22747
dc.identifier.endpage70
dc.identifier.issn2149-2042
dc.identifier.issn2149-4606
dc.identifier.issue1
dc.identifier.pmid35306787
dc.identifier.scopus2-s2.0-85128375146
dc.identifier.scopusqualityQ2
dc.identifier.startpage62
dc.identifier.trdizinid523652
dc.identifier.urihttps://doi.org/10.4274/MMJ.galenos.2022.22747
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/523652
dc.identifier.urihttps://hdl.handle.net/20.500.14730/12715
dc.identifier.volume37
dc.identifier.wosWOS:001109591700008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofMedeniyet Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectGenetic counseling
dc.subjectlow unconjugated estriol
dc.subjectmaternal serum screening
dc.subjectprenatal cytogenetics
dc.subjectSmith Lemli Opitz syndrome
dc.subjectsteroid sulfatase deficiency
dc.titleHow to Manage Low Estriol Levels in Pregnancies, One Center Experience
dc.typeArticle

Dosyalar